Abstract: The present invention relates to the use of caprylic and capric triglycerides, a combination of caprylic and capric triglycerides and melatonin or a derivative thereof or a composition containing the caprylic and capric triglycerides alone or in combination with melatonin or a derivative thereof for the treatment of a disease or condition mediated by a filaggrin or collagen deficiency.

Abstract: It relates to a combination comprising a) rhamnose or a rhamnose-rich polysaccharide; b) a film-forming agent; and c) one or more further active agents selected from: i) a hyaluronic acid derivative selected from the group consisting of hyaluronic acid, a pharmaceutically or cosmetically acceptable salt thereof, and a cationized hyaluronic acid, ii) a silanol compound, and iii) an extract of Pistacia lentiscus; for use in the treatment and/or prevention of fungal infections in human beings. It also relates to this combination per se, and to pharmaceutical or cosmetic topical nail composition containing it.

Abstract: It relates to a rhamnose or a rhamnose-rich polysaccharide for use in the treatment and/or prevention of fungal infections in human beings. It also relates to a combination of rhamnose or a rhamnose-rich polysaccharide and a further antifungal agent for use in the treatment and/or prevention of fungal infections in human beings. It also relates to pharmaceutical or cosmetic composition comprising an effective amount of rhamnose or a rhamnose-rich polysaccharide for use in the treatment and/or prevention of fungal infections in human beings.

Abstract: It relates to a rhamnose or a rhamnose-rich polysaccharide for use in the treatment and/or prevention of fungal infections in human beings. It also relates to a combination of rhamnose or a rhamnose-rich polysaccharide and a further antifungal agent for use in the treatment and/or prevention of fungal infections in human beings. It also relates to pharmaceutical or cosmetic composition comprising an effective amount of rhamnose or a rhamnose-rich polysaccharide for use in the treatment and/or prevention of fungal infections in human beings.

Abstract: The present invention relates to the use of photolyase enzymes to reduce or improve subclinical skin field cancerization associated with actinic keratosis or non-melanoma skin cancer (NMSC) and methods for the therapeutic treatment of subclinical field cancerization associated with actinic keratosis and/or non-melanoma skin cancer (NMSC).

Abstract: This invention refers to the use of mitochondrial DNA as a quantitative biomarker of neurodegenerative diseases, preferably Alzheimer's disease, as well as a method and a diagnostic and/or prognostic kit of these diseases through the use of this biomarker.

Abstract: The present invention relates to the use of photolyase enzymes to reduce or improve subclinical skin field cancerization associated with actinic keratosis or non-melanoma skin cancer (NMSC) and methods for the therapeutic treatment of subclinical field cancerization associated with actinic keratosis and/or non-melanoma skin cancer (NMSC).

Abstract: The invention relates to a series of compounds useful for the production of drugs or pharmaceutical compositions for the treatment or prevention of human neurological diseases, preferably neurodegenerative diseases, which inhibit the activity of the human NP1 protein which acts as an inducer of neurodegeneration and neural apoptosis. Said compounds include iRNA inhibitors of the gene expression of the NP1 gene and specific antibodies of the human NP1 protein, as well as peptides derived from same, which can be used in passive and active immunisation methods respectively against said diseases.

Abstract: The present invention refers to a combination of at least 2 UV-absorbing active substances (A) and (B), wherein the UV-absorbing active substance (A) is at least one heptaazaphenalene compound of the general formula (I), which is defined in the description and the UV-ab-sorbing active substance (B) is at least one compound which has its ab-sorption maximum ?maX(B) in the range of UV-A or UV-B radiation.

Abstract: The present invention relates to a humanized, non-human mammal model, preferably a humanized mouse model, with an engrafted portion of human skin having hyper-patient sensitivity to ultra violet (UV) light, and a method for preparing such non-human mammal model and its use for studying acute and long term effects on human skin by exposure to UV light and for testing topically or systematically applied or administered substances for their capability to prevent, repair and/or cure damages of such exposed human skin. This mouse model comprises an engrafted portion of human skin based on skin cells of a human Xeroderma pigmentosum (XP) or Gorlin's Syndrome (GS) patient. XP and GS are rare human autosomal disorders characterized clinically by hypersensitivity to UV light, especially to UVB rays, and high predisposition for developing skin cancers on sunlight exposed skin areas.

Abstract: The use of a compound possessing functional antagonist properties at the NMDA receptor complex through a specific action at the associated strychnine-insensitive glycine site to improve cognition in normal humans and to treat cognitive deficits resulting from chronic neuronal degeneration, acute brain injury, hypoxia, or other neurological disorders is provided. The compounds possessing functional antagonist properties comprise 1-aminocyclopropanecarboxylic acid, and its pharmaceutically acceptable esters, salts, and acid addition salts or 7-chlorokynurenic acid, and its pharmaceutically acceptable esters, amides, salts, ethers, and acid addition salts.

Abstract: A method is disclosed for the treatment of mood disorders, including major depression, by administering an effective mood disorder treating amount of a compound possessing functional antagonist properties for the N-methyl-D-aspartate receptor complex.